Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes.

Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF.

Am J Hematol. 2012 Nov;87(11):1006-9. doi: 10.1002/ajh.23303. Epub 2012 Aug 1.

2.

Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities.

Sevindik OG, Guc Z, Kahraman S, Medeni Solmaz S, Katgi A, Acar C, Alacacioglu I, Piskin O, Ozsan GH, Demirkan F, Undar B, Ozcan MA.

Leuk Lymphoma. 2015;56(9):2552-5. doi: 10.3109/10428194.2015.1014362. Epub 2015 Mar 6.

PMID:
25669924
3.

Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.

Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF.

Cancer. 2012 May 15;118(10):2659-64. doi: 10.1002/cncr.26567. Epub 2011 Sep 28.

4.

Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.

Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, Caocci G, Stauder R, Selleslag D, Sprangers M, Platzbecker U, Ricco A, Sanpaolo G, Beyne-Rauzy O, Buccisano F, Palumbo GA, Bowen D, Nguyen K, Niscola P, Vignetti M, Mandelli F.

Lancet Oncol. 2015 Nov;16(15):1506-14. doi: 10.1016/S1470-2045(15)00206-5. Epub 2015 Sep 21.

PMID:
26404501
5.

Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.

van Spronsen MF, Ossenkoppele GJ, Westers TM, van de Loosdrecht AA.

Eur J Cancer. 2016 Mar;56:10-20. doi: 10.1016/j.ejca.2015.12.004. Epub 2016 Jan 19.

PMID:
26798967
6.

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.

Kao JM, McMillan A, Greenberg PL.

Am J Hematol. 2008 Oct;83(10):765-70. doi: 10.1002/ajh.21249.

7.

Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.

Fega KR, Abel GA, Motyckova G, Sherman AE, DeAngelo DJ, Steensma DP, Galinsky I, Wadleigh M, Stone RM, Driver JA.

J Geriatr Oncol. 2015 Jul;6(4):288-98. doi: 10.1016/j.jgo.2015.05.003. Epub 2015 Jun 11.

8.

Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?

Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS; MDS Clinical Research Consortium (Funded by Edward P. Evans Foundation).

Am J Hematol. 2015 Nov;90(11):1036-40. doi: 10.1002/ajh.24173.

9.

Prognostic analysis of refractory anaemia in adult myelodysplastic syndromes.

Wang XQ, Chen ZX, Chen SC, Lin GW, Ji MR, Liang JY, Liu DD, Li DG, Ma Y.

Chin Med J (Engl). 2008 Sep 20;121(18):1787-91.

PMID:
19080358
10.

Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.

Lee YJ, Park SW, Lee IH, Ahn JS, Kim HJ, Chung JS, Shin HJ, Lee WS, Lee SM, Joo YD, Kim H, Lee HS, Kim YS, Cho YY, Moon JH, Sohn SK.

Ann Hematol. 2016 Oct;95(11):1795-804. doi: 10.1007/s00277-016-2759-y. Epub 2016 Aug 17.

PMID:
27530461
11.

Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.

Voso MT, Fenu S, Latagliata R, Buccisano F, Piciocchi A, Aloe-Spiriti MA, Breccia M, Criscuolo M, Andriani A, Mancini S, Niscola P, Naso V, Nobile C, Piccioni AL, D'Andrea M, D'Addosio A, Leone G, Venditti A.

J Clin Oncol. 2013 Jul 20;31(21):2671-7. doi: 10.1200/JCO.2012.48.0764. Epub 2013 Jun 24.

PMID:
23796988
12.

Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.

Falantes JF, Calderón C, Márquez Malaver FJ, Alonso D, Martín Noya A, Carrillo E, Martino ML, Montero I, González J, Parody R, Espigado I, Pérez-Simón JA.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):144-52. doi: 10.1016/j.clml.2012.09.013. Epub 2012 Nov 6.

PMID:
23137720
13.

Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.

van Spronsen MF, Ossenkoppele GJ, Holman R, van de Loosdrecht AA.

Eur J Cancer. 2014 Dec;50(18):3198-205. doi: 10.1016/j.ejca.2014.09.016. Epub 2014 Oct 28.

PMID:
25454415
14.

Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.

Park MJ, Kim HJ, Kim SH, Kim DH, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW.

Eur J Haematol. 2008 Nov;81(5):364-73. doi: 10.1111/j.1600-0609.2008.01124.x. Epub 2008 Jul 10.

PMID:
18637029
15.

Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.

Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S, Lei X, Shan J, Kantarjian HM, Suarez-Almazor ME.

J Clin Oncol. 2011 Jun 1;29(16):2240-6. doi: 10.1200/JCO.2010.31.3353. Epub 2011 May 2.

16.

Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.

Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancet J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C.

Biol Blood Marrow Transplant. 2011 Mar;17(3):384-93. doi: 10.1016/j.bbmt.2010.07.011. Epub 2010 Jul 22.

17.

Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.

Gauthier J, Damaj G, Langlois C, Robin M, Michallet M, Chevallier P, Beguin Y, N'guyen S, Bories P, Blaise D, Cornillon J, Clavert A, Mohty M, Huynh A, Thiébaut-Bertrand A, Vigouroux S, Duhamel A, Yakoub-Agha I.

Transplantation. 2015 Aug;99(8):1672-80. doi: 10.1097/TP.0000000000000649.

PMID:
25769079
18.

Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms.

Pardanani A, Lasho TL, Finke CM, Rajkumar SV, Singh PP, Ketterling RP, Hanson CA, Katzmann JA, Tefferi A.

J Clin Oncol. 2012 Apr 1;30(10):1087-94. doi: 10.1200/JCO.2011.39.0310. Epub 2012 Feb 13.

PMID:
22331938
19.

Serum ferritin is an independent prognostic factor in Chinese with myelodysplastic syndromes classified as IPSS Intermediate-1.

Li B, Xu Z, Gale RP, Qin T, Zhang Y, Xiao Z.

Acta Haematol. 2013;129(4):243-50. doi: 10.1159/000345428. Epub 2013 Jan 15.

PMID:
23328695
20.

Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.

Loeffler-Ragg J, Germing U, Sperr WR, Herrmann H, Zwierzina H, Valent P, Ulmer H, Stauder R.

Crit Rev Oncol Hematol. 2011 May;78(2):150-61. doi: 10.1016/j.critrevonc.2010.05.008. Epub 2010 Jun 26.

PMID:
20580567

Supplemental Content

Support Center